The shares of this company surged 17% after it announced new products for the market and set an ambitious target of achieving Rs 1,000 crore over the next 5 years. This has boosted the morale of the investors.
Price MovementÂ
With a market capitalization of Rs 3,490 crore, the shares of Morepen Laboratories Ltd are currently trading at Rs 63.7 per share, down by 37 percent from its 52-week high of Rs 101 per share. During the last one year, the stock has given a positive return of 23.54 percent.
About the announcement
On Thursday, the company announced a key business update, which caused the stock to surge 16% during today’s trading session. The company announced the launch of four new products in the market, namely Ticapen, UdoFix, LycoMore, and Acifix, addressing critical needs in cardiology, hepatology, nutrition, and diabetology, marking a strategic expansion of its branded formulations business in India.
It also launched Empamore in March, reflecting a strong push towards innovation-driven, specialty-focused therapeutics. Additionally, the company has also disclosed of achieving Rs 1,000 crore, from Rs 325 crores, over the next five years.
Also read: Stock under ₹200 skyrockets 13% after ₹752 Cr partnership with Govt of Singapore Investment Corp
Product Highlights
Ticapen (Ticagrelor 60mg/90mg) is a cost-effective, clinically proven antiplatelet therapy for ACS, Angina, and MI. Produced in USFDA-approved facilities, it boasts a distinctive 4×14 patient-friendly pack with Day/Night compliance markers and high-quality matte foil packaging, providing universal access at a competitive price.
UdoFix (Ursodeoxycholic Acid 150/300mg) redefines liver health with 98.23% better dissolution. Made in a USFDA-approved plant with anti-counterfeit Holosec packaging, its price is ₹39.9/tab, providing an economical substitute to market leaders.
LycoMore Syrup pairs Lycopene with key vitamins and minerals to enhance immunity and recovery. In a glass bottle for greater shelf life, it is easy on the palate with a nutrient-dense formula, guaranteeing patient convenience and adherence.
Acifix Raft Suspension offers rapid, targeted relief for GERD, reflux, and heartburn with a swift-acting raft mechanism and novel paan flavor, enhancing patient compliance for optimal acid control.
About the company
Morepen Laboratories manufactures and markets pharmaceuticals such as APIs, health devices, and OTC products in India and overseas. It provides treatment for diseases such as allergies, diabetes, and hypertension, and diagnostic products such as thermometers and glucose meters. Dr. Morepen’s portfolio consists of products for fever, pain, acidity, and overall well-being.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
